French MedTech RDS Secures €14M In Series A Round

The round was led by SPI (Sociétés de Projets Industriels), managed by Bpifrance on behalf of the French state, with Critical Path Ventures, MACSF, Capital Grand Est, and other existing investors participating.

This funding brings RDS’s total capital raised to €28 million, including the €14 million in government-backed support through the France 2030 investment plan.

“This investment gives us the means to ramp up our sales growth in Europe, consolidate the clinical and health economic value of MultiSense, and get ready for market launch in North America,” said Elie Lobel, CEO of RDS.

He added: “These funds mean we can roll out our solution more widely to hospitals, expand its positive impact for patients and care teams, and provide reliable, continuous, clinically validated remote monitoring to as many facilities as possible. The funds raised are a testament to our investors’ enduring confidence in this project and the team.”

Read Also - UK EdTech MyEdSpace Secures €12.8M In Series A Round To Fuel US Expansion

Founded in 2020, RDS focuses on remote patient monitoring with its flagship solution, MultiSense. The company develops, manufactures and markets this wearable medical device, supported by an international team and collaborations with research projects like DARE and 5G-OR. Incubated at SEMIA/Quest for Health and accelerated by PariSanté Campus, RDS aims to redefine telemonitoring standards through patented, eco-conscious technology.

MultiSense combines a wearable patch with a cloud-based platform and support services, continuously tracking six key health parameters, including heart rate, respiratory rate, and oxygen saturation.

Sustainability is central to its design: the device can be cleaned, refurbished, and reused to minimize its carbon footprint. MultiSense also supports short-stay hospitalization protocols, helping reduce hospital stays, ensure safer discharges and improve patient quality of life.

“France 2030 is proud to have supported this project since 2020 and to work today with SPI on the rapid industrialisation and effective deployment of the solution for the benefit of patients. RDS’ story clearly shows how France 2030 is capable of transitioning a project from the lab stage to becoming an international champion,” said Bruno Bonnell, Secretary General for Investment, in charge of France 2030.

Compared to peers, RDS’s Series A is moderate in size but significant, particularly in the MedTech hardware and clinical trials sector. Its focus on industrial scaling, reimbursement, and European expansion aligns closely with areas investors have valued in similar companies.

“We are delighted to be supporting RDS in this critical phase of its development,” said Magali Joëssel, director of the SPI fund at Bpifrance. “This funding gives the company the means to become a leading player in post-operative remote monitoring through MultiSense, and a pioneer in the medicine of the future. By scaling the manufacturing of its solution, RDS fully embodies the principle of the SPI fund: funding the industrialisation of innovative technologies that will bring growth and jobs to France.”

RDS’s clinically validated technology is already deployed in 15 hospitals across France, Belgium, and Germany. Over the past year, the device was added to the approved supplies lists of RESAH and UniHA, France’s leading public hospital purchasing bodies.

The company plans to create several hundred new jobs by 2035, expanding its sales team to meet growing demand for MultiSense. Funding will also support industrialisation in France, gradually increasing production and refurbishment capacity.

Additionally, RDS will launch complementary clinical trials to strengthen reimbursement applications across Europe and is preparing for FDA registration, targeting a US market launch in 2028.

“We believe that the key to transforming the healthcare system is useful innovation and industrial ambition,” said Nicolas Foessel of Critical Path Ventures. “With our investment in RDS, we are backing a team that combines technological excellence with clinical impact and a long-term vision for medicine, with emphasis on a more preventive, smoother and human approach. MultiSense exemplifies this positioning, enabling continuous monitoring and meeting patients’ particular needs away from the hospital setting.”

Alongside the funding round, Laurent Monnin, Senior Investment Director at Bpifrance, and Nicolas Foessel of Critical Path Ventures, have joined RDS’s strategic board.

“The funding provided by SPI and Critical Path Ventures is a real asset for RDS, which will be able to ramp-up activities after a launch phase to which MACSF and Capital Grand Est have contributed,” said Jean-François Rax, partner at Capital Grand Est.

About RDS

RDS develops innovative remote patient monitoring solutions, including its wearable MultiSense patch and cloud platform, to advance patient care pathways. Combining clinical accuracy, sustainability and tech-driven insights, RDS supports hospitals across Europe, reduces hospital stays, and enhances patient outcomes, while preparing for expansion into new markets, including the US.